Imprinting and clonality of human NK cell memory

This project aims to uncover the signals and mechanisms behind the clonal memory of human NK cells to enhance their effector functions and identify new targets for anti-tumor therapies.

Subsidie
€ 2.372.750
2022

Projectdetails

Introduction

The pool of innate immune effector cells is wired to rapidly respond to pathogens, whereas only few specificities within the naïve adaptive repertoire expand clonally, undergo epigenetic remodelling and differentiate into effector and memory cells. However, innate cells can differentiate upon pathogen encounter and remember past experiences as well, thereby challenging this strict dichotomy.

Background

In particular, us and others have shown that human memory Natural Killer (NK) cells with global epigenetic remodelling can be generated in response to specific signals during cytomegalovirus (CMV) infection. We have recently identified two major types of open chromatin domains in human memory NK (mNK) cells ex vivo:

  1. A shared signature featured by all mNK cells across CMV-seropositive donors (“public memory”).
  2. A diverse set of unique open chromatin regions associated with the drastic expansions of individual and stable NK cell clones (“private memory”).

Based on this unexpected finding, we hypothesise that the shared and the unique clonal memory might provide mNK cells with increased fitness and high effector potential, but also enhance the risk of oncogenic mutations.

Project Goals

The ultimate goal of this project is to identify the signals and molecular mechanisms driving acquisition, selection and maintenance of human NK cell public and private clonal memory.

Methodology

To this end, we will combine:

  • Multiomic single cell assays
  • Lineage tracing of human NK cells from healthy donors and patients ex vivo, or under various stimuli in vitro
  • Genome-wide CRISPR perturbation studies to directly link ex vivo features with functional readouts.

Expected Outcomes

Success of this project will not only lead to new insights into the key networks promoting persistence and effector functions of mNK cells, but also reveal promising novel targets for cellular anti-tumour therapies.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.372.750
Totale projectbegroting€ 2.372.750

Tijdlijn

Startdatum1-9-2022
Einddatum31-8-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • CHARITE - UNIVERSITAETSMEDIZIN BERLINpenvoerder
  • DEUTSCHES RHEUMA FORSCHUNGSZENTRUMBERLIN

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Activation and switch of fates in T lymphocytes.

This project aims to model the fate choices of naïve and memory CD8+ T cells using experimental immunology and systems biology to enhance vaccine design and improve responses to infections and cancer.

€ 2.625.000
ERC Starting...

What does your blood remember? The memory of hematopoietic stem cells.

This project aims to investigate how hematopoietic stem cells develop adaptive memory to environmental stress, enhancing blood cell responses and improving transplantation strategies.

€ 2.500.000
ERC Starting...

Tracing virus-specific CD8+ T cell clonotype zonation and function in humans

This project aims to redefine the role and distribution of CD8+ T cells in viral immunity using single-cell technologies, focusing on their function against SARS-CoV-2 and informing future vaccine development.

€ 1.499.932
ERC Starting...

Epigenetic and transcriptional basis of memory engram plasticity

This project aims to uncover the epigenetic and transcriptional mechanisms of memory engram cells during consolidation and retrieval using advanced genomics and functional analysis techniques.

€ 1.499.948
ERC Consolid...

Early life imprinting of B cell memory and its role in adult immunity

This project aims to investigate how early life derived B cells (ELO-B) shape adult immune responses through their unique imprinting and contributions to immunological memory and tolerance.

€ 1.999.983

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

Melanoom specifieke NK cel therapie

Dit project onderzoekt de ontwikkeling van patiënt specifieke NK-celtherapie om hindernissen bij de behandeling van melanoom met NK-cellen te overwinnen.

€ 20.000
EIC Pathfinder

Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapies

The HyperTargIPS-NK project aims to develop a scalable, off-the-shelf NK cell therapy using iPS cells to target and treat lethal cancers like pancreatic cancer, glioblastoma, and AML.

€ 3.798.713
Mkb-innovati...

PREDICT - Towards a PREDICTable combination therapy

Het project richt zich op het ontwikkelen van een datagestuurde combinatie van immuunsuppressie en NK-celtherapie om de uitkomst van kankerbehandelingen te voorspellen en te verbeteren.

€ 165.355